Suppr超能文献

用于治疗绝经后骨质疏松症的氟化物。

Fluoride for treating postmenopausal osteoporosis.

作者信息

Haguenauer D, Welch V, Shea B, Tugwell P, Wells G

机构信息

Clinical Epidemiologist, 135 Riverdale Avenue, Ottawa, Ontario, Canada, K1S-1R1.

出版信息

Cochrane Database Syst Rev. 2000;2000(4):CD002825. doi: 10.1002/14651858.CD002825.

Abstract

OBJECTIVES

To assess the efficacy of fluoride therapy on bone loss, vertebral and non-vertebral fractures and side effects in postmenopausal women.

SEARCH STRATEGY

We searched Medline, Current Contents and the Cochrane Controlled Trial Registry up to December 1998.

SELECTION CRITERIA

Two independent reviewers selected RCTs which met predetermined inclusion criteria.

DATA COLLECTION AND ANALYSIS

Two reviewers independently extracted data using predetermined forms and assessed the methodological quality of the trials using a validated scale. For dichotomous outcomes, relative risks (RR) were calculated and for continuous outcomes, weighted mean differences (WMD) of percentage change from baseline were calculated. Where heterogeneity existed (determined by a chi-square test) a random effects model was used.

MAIN RESULTS

Eleven studies (1429 subjects) met the inclusion criteria. The increase in lumbar spine bone mineral density (BMD) was found to be higher in the treatment group than in the control group with a WMD 8.1% (95%CI: 7.15,9.09) after two years of treatment and 16.1%(95%CI: 14.65,17.5) after four years. The RR for new vertebral fractures was not significant at two years [0.87 (95%CI: 0.51,1.46)] or at four years [0.9(95%CI: 0.71,1.14)]. The RR for new non-vertebral fractures was not significant at two years 1.2(95%CI: 0.68,2.1) but was increased at four years in the treated group 1.85(95%CI: 1.36,2.5), especially if used at high doses and in a non slow release form. The RR for gastrointestinal side effects was not significant at two years 2.18(95%CI: 0.86,1.21) but was increased at four years in the treated group 2.18(95%CI: 1.69,4.57) especially if fluoride was used at high doses and in a non slow release form. The number of withdrawals and dropouts was not different between treated and control groups at two and four years.

REVIEWER'S CONCLUSIONS: Although fluoride has an ability to increase BMD at lumbar spine, it does not result in a reduction of vertebral fractures. In increasing the dose of fluoride, one increases the risk of non-vertebral fracture and gastrointestinal side effects without any effect on the vertebral fracture rate.

摘要

目的

评估氟化物疗法对绝经后女性骨质流失、椎体和非椎体骨折以及副作用的疗效。

检索策略

我们检索了截至1998年12月的医学索引数据库(Medline)、《现刊目次》(Current Contents)和Cochrane对照试验注册库。

选择标准

两名独立评审员选择符合预定纳入标准的随机对照试验(RCT)。

数据收集与分析

两名评审员使用预定表格独立提取数据,并使用经过验证的量表评估试验的方法学质量。对于二分法结局,计算相对风险(RR);对于连续性结局,计算自基线起百分比变化的加权平均差(WMD)。若存在异质性(通过卡方检验确定),则使用随机效应模型。

主要结果

11项研究(1429名受试者)符合纳入标准。发现治疗组腰椎骨矿物质密度(BMD)的增加高于对照组,治疗两年后的WMD为8.1%(95%CI:7.15,9.09),四年后的WMD为16.1%(95%CI:14.65,17.5)。新椎体骨折的RR在两年时[0.87(95%CI:0.51,1.46)]和四年时[0.9(95%CI:0.71,1.14)]均无显著意义。新非椎体骨折的RR在两年时为1.2(95%CI:0.68,2.1)无显著意义,但在四年时治疗组增加至1.85(95%CI:1.36,2.5),尤其是高剂量且非缓释剂型使用时。胃肠道副作用的RR在两年时为2.18(95%CI:0.86,1.21)无显著意义,但在四年时治疗组增加至2.18(95%CI:1.69,4.57),尤其是高剂量且非缓释剂型使用氟化物时。两年和四年时,治疗组与对照组的退出和失访人数无差异。

评审员结论

尽管氟化物有增加腰椎BMD的能力,但并未降低椎体骨折发生率。增加氟化物剂量会增加非椎体骨折和胃肠道副作用的风险,而对椎体骨折率无任何影响。

相似文献

1
Fluoride for treating postmenopausal osteoporosis.用于治疗绝经后骨质疏松症的氟化物。
Cochrane Database Syst Rev. 2000;2000(4):CD002825. doi: 10.1002/14651858.CD002825.
2
8
Sertindole for schizophrenia.用于治疗精神分裂症的舍吲哚。
Cochrane Database Syst Rev. 2005 Jul 20;2005(3):CD001715. doi: 10.1002/14651858.CD001715.pub2.
10
Strontium ranelate for preventing and treating postmenopausal osteoporosis.雷奈酸锶用于预防和治疗绝经后骨质疏松症。
Cochrane Database Syst Rev. 2006 Oct 18;2006(4):CD005326. doi: 10.1002/14651858.CD005326.pub3.

引用本文的文献

1
Research progress of diabetic osteoporosis: a comprehensive review.糖尿病性骨质疏松症的研究进展:综述
Front Endocrinol (Lausanne). 2025 Sep 2;16:1595228. doi: 10.3389/fendo.2025.1595228. eCollection 2025.
2
Osteoporosis treatment: current drugs and future developments.骨质疏松症的治疗:当前药物与未来发展
Front Pharmacol. 2024 Aug 12;15:1456796. doi: 10.3389/fphar.2024.1456796. eCollection 2024.
5
Chemical Aspects of Human and Environmental Overload with Fluorine.氟化物对人类和环境的超负荷影响的化学方面。
Chem Rev. 2021 Apr 28;121(8):4678-4742. doi: 10.1021/acs.chemrev.0c01263. Epub 2021 Mar 16.
7
The Fluoride Debate: The Pros and Cons of Fluoridation.氟化物辩论:氟化的利弊
Prev Nutr Food Sci. 2018 Sep;23(3):171-180. doi: 10.3746/pnf.2018.23.3.171. Epub 2018 Sep 30.
10
Chinese herbal medicines for treating osteoporosis.用于治疗骨质疏松症的中草药。
Cochrane Database Syst Rev. 2014 Mar 6;2014(3):CD005467. doi: 10.1002/14651858.CD005467.pub2.

本文引用的文献

2
Fluoride for the treatment of postmenopausal osteoporotic fractures: a meta-analysis.
Osteoporos Int. 2000;11(9):727-38. doi: 10.1007/s001980070051.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验